| Literature DB >> 31768300 |
Alicia Fournier1,2, Olivier Luminet3,4, Michael Dambrun5, Frédéric Dutheil5,6,7, Sonia Pellissier8, Laurie Mondillon5.
Abstract
BACKGROUND: Recent studies have shown that people with high alexithymia scores have decreased interoceptive abilities, which can be associated with psychological and physical disorders. Early assessments of the alexithymia trait included the evaluation of these abilities through the dimension measuring the difficulty in identifying and distinguishing between feelings and bodily sensations (the 26-item Toronto Alexithymia Scale; TAS-26). The revised version of the TAS, the TAS-20, contains a three-factor solution that does not involve a dimension assessing interoceptive abilities. However, the three items allowing the evaluation of these abilities are still present in the TAS-20. In this context, we hypothesized that the 3 items which assess interoceptive abilities in the TAS-20 should constitute an independent factor. In addition to exploring the internal structure of the TAS-20, we examined its external validity by assessing the relationships between the new factors and self-reported measures of personality trait and psychological and physical health.Entities:
Keywords: Alexithymia; Factorial analysis; Interoceptive abilities; Toronto Alexithymia Scale
Year: 2019 PMID: 31768300 PMCID: PMC6874858 DOI: 10.7717/peerj.7615
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Socio-demographic, general health, and psychological data for both samples.
| Total sample | Total sample | ||
|---|---|---|---|
| Socio-demographic data | |||
| Number of participants | 253 | 287 | |
| Percentage of Women | 69.57% | 87.8% | <0.001 |
| Age | 29.65 ± 13.82 | 19.56 ± 1.58 | <0.001 |
| Health data | |||
| Cardiovascular disease, | 13 (5.14) | 13 (4.53) | 0.841 |
| Eating disorders, | 24 (9.49) | 22 (7.66) | 0.537 |
| Somatic disorders, | 11 (4.35) | 12 (4.18) | 1 |
| Medication intake, | 34 (13.44) | 32 (11.14) | 0.43 |
| Anxiolytics | 3 | 5 | |
| Antidepressants | 6 | 4 | |
| Anti-inflammatory drugs | 2 | 1 | |
| Antihistamines | 2 | 5 | |
| Migraine medications | 1 | 4 | |
| Asthma medications | 4 | 1 | |
| Others | 19 | 16 | |
| Psychological data | |||
| TAS-20 (/100) | 48.58 ± 10.87 | 51.59 ± 11.62 | 0.002 |
| DIF (/35) | 15.09 ± 5.02 | 18.79 ± 6.33 | <0.001 |
| DDF (/25) | 13.41 ± 4.53 | 15.19 ± 4.70 | <0.001 |
| EOT (/40) | 20.08 ± 4.70 | 17.61 ± 4.15 | <0.001 |
| STAI-T (/80) | 42.14 ± 9.66 | 45.53 ± 9.71 | <0.001 |
| HADS-D (/21) | 3.71 ± 2.90 | – | |
| BDI-13 (/39) | – | 18.85 ± 4.56 | |
| BFI-N (/40) | 21.02 ± 6.94 | 23.62 ± 6.80 | <0.001 |
| PSS (/40) | 26.74 ± 7.48 | 29.40 ± 7.47 | <0.001 |
| Brief Cope | |||
| Functional coping (/8) | 5.20 ± 1.30 | 5.14 ± 1.10 | 0.535 |
| Coping with varying functionality (/8) | 4.43 ± 1.02 | 4.52 ± 0.92 | 0.279 |
| Dysfunctional coping (/8) | 3.03 ± 0.86 | 3.22 ± 0.83 | 0.008 |
Notes:
p < 0.01.
p < 0.001.
Data represents means ± SD.
Regards differences between Study 1 and Study 2; ANOVA Test or Chi2–Test. To compare the samples, alexithymia scores from Study 1 were transformed into a 5-point Likert scale.
The “others” category included drugs with a low frequency of use such as beta-blocker or immunosuppressant. The detailed list of medications may include multiple intakes. The same participant could be included in two categories of drugs.
Loadings after Oblimin rotation from the EFA of the TAS-20, from the EFA of the TAS without items 16 and 20, and comparative attribution of items in Study 1.
| Items | Factor (F) | Latent factor (LF) | Theoretical attribution | New attribution | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| F1 | F2 | F3 | F4 | F5 | LF1 | LF2 | LF3 | LF4 | |||
| 1 | DIF | LF1 | |||||||||
| 2 | 0.41 | 0.37 | DDF | LF1 | |||||||
| 3 | DIF | LF3 | |||||||||
| 4 | 0.38 | DDF | LF4 | ||||||||
| 5 | EOT | LF2 | |||||||||
| 6 | DIF | LF1 | |||||||||
| 7 | DIF | LF3 | |||||||||
| 8 | EOT | LF2 | |||||||||
| 9 | DIF | LF1 | |||||||||
| 10 | EOT | LF2 | |||||||||
| 11 | DDF | LF1 | |||||||||
| 12 | 0.30 | DDF | LF4 | ||||||||
| 13 | DIF | LF1 | |||||||||
| 14 | DIF | LF1 | |||||||||
| 15 | 0.35 | 0.37 | EOT | LF4 | |||||||
| 16 | – | – | – | – | EOT | – | |||||
| 17 | DDF | LF4 | |||||||||
| 18 | EOT | LF2 | |||||||||
| 19 | EOT | LF2 | |||||||||
| 20 | – | – | – | – | EOT | – | |||||
| Eigenvalues | 5.49 | 2.15 | 1.55 | 1.20 | 1.12 | 5.47 | 2.06 | 1.47 | 1.09 | ||
| % of variance | 27.44 | 10.76 | 7.74 | 5.98 | 5.61 | 30.37 | 11.43 | 8.17 | 6.04 | ||
| α | 0.85 | 0.62 | 0.66 | 0.36 | 0.68 | 0.85 | 0.62 | 0.66 | 0.68 | ||
Note:
Factor loadings are highlighted in bold type. For easy reading, all values of loading <0.30 were not reported, except if they explained the factor.
Loadings after Oblimin rotation from the EFA of the TAS without items 16 and 20, and comparative attribution of items in Study 2.
| Items | Factor (F) | Factor (F) | Latent factor (LF) | Theoretical attribution | New attribution | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F1 | F2 | F3 | F4 | F5 | F6 | F1 | F2 | F3 | F4 | F5 | LF1 | LF2 | LF3 | LF4 | |||
| 1 | DIF | LF1 | |||||||||||||||
| 2 | DDF | LF1 | |||||||||||||||
| 3 | DIF | LF3 | |||||||||||||||
| 4 | 0.31 | DDF | LF1 | ||||||||||||||
| 5 | EOT | LF2 | |||||||||||||||
| 6 | 0.36 | DIF | LF1 | ||||||||||||||
| 7 | DIF | LF3 | |||||||||||||||
| 8 | EOT | LF2 | |||||||||||||||
| 9 | DIF | LF1 | |||||||||||||||
| 10 | EOT | LF2 | |||||||||||||||
| 11 | 0.33 | DDF | LF4 | ||||||||||||||
| 12 | DDF | LF4 | |||||||||||||||
| 13 | 0.33 | 0.35 | DIF | LF1 | |||||||||||||
| 14 | 0.40 | DIF | LF1 | ||||||||||||||
| 15 | EOT | LF4 | |||||||||||||||
| 16 | – | – | – | – | – | – | – | – | – | EOT | – | ||||||
| 17 | DDF | LF4 | |||||||||||||||
| 18 | EOT | LF2 | |||||||||||||||
| 19 | EOT | LF2 | |||||||||||||||
| 20 | – | – | – | – | – | – | – | – | – | EOT | – | ||||||
| Eigenvalues | 5.57 | 2.07 | 1.49 | 1.20 | 1.12 | 1.07 | 5.51 | 1.87 | 1.47 | 1.10 | 1.02 | 5.51 | 1.87 | 1.10 | 1.47 | ||
| % of variance | 27.85 | 10.36 | 7.43 | 6.00 | 5.59 | 5.34 | 30.61 | 10.39 | 8.14 | 6.13 | 5.67 | 30.61 | 10.39 | 6.13 | 8.14 | ||
| α | 0.88 | 0.51 | 0.70 | 0.71 | 0.43 | 0.37 | 0.86 | 0.51 | 0.70 | 0.71 | – | 0.88 | 0.51 | 0.64 | 0.70 | ||
Note:
Factor loadings are highlighted in bold type. For easy reading, all values of loading <0.30 were not reported, except if they explained the factor.
Detailed results of the multivariate logistic regression analyses.
| Study 1 | Study 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Somatic disorders | Eating disorders | Medication intake | Cardiovascular diseases | Somatic disorders | Eating disorders | Medication intake | Cardiovascular diseases | ||
| Latent Factor 1 (LF1) | −0.10 | 0.13 | 0.01 | 0.07 | −0.07 | −0.06 | 0.04 | 0.06 | |
| Wald | 1.19 | 5.64 | 0.05 | 0.78 | 1.01 | 1.53 | 1.1 | 0.89 | |
| 0.9 | 1.14 | 1.01 | 1.07 | 0.94 | 0.94 | 1.04 | 1.06 | ||
| 0.276 | 0.018 | 0.820 | 0.376 | 0.315 | 0.216 | 0.294 | 0.346 | ||
| Latent Factor 2 (LF2) | −0.06 | −0.05 | −0.01 | −0.14 | −0.06 | −0.03 | −0.07 | 0.08 | |
| Wald | 0.23 | 0.32 | 0.01 | 1.46 | 0.28 | 0.121 | 1.05 | 0.56 | |
| 0.94 | 0.95 | 0.99 | 0.87 | 0.94 | 0.97 | 0.93 | 1.08 | ||
| 0.632 | 0.570 | 0.934 | 0.227 | 0.597 | 0.728 | 0.305 | 0.454 | ||
| Latent Factor 3 (LF3) | 0.62 | 0.14 | 0.39 | 0.17 | 0.74 | 0.33 | 0.22 | 0.34 | |
| Wald | 11.40 | 0.86 | 9.06 | 0.75 | 15.68 | 8.72 | 5.40 | 5.22 | |
| 1.86 | 1.15 | 1.47 | 1.18 | 2.09 | 1.40 | 1.25 | 1.41 | ||
| 0.001 | 0.354 | 0.003 | 0.387 | <0.001 | 0.003 | 0.020 | 0.022 | ||
| Latent Factor 4 (LF4) | 0.01 | −0.03 | −0.17 | −0.001 | −0.13 | 0.01 | −0.12 | −0.10 | |
| Wald | 0.004 | 0.08 | 3.87 | 0.00 | 1.45 | 0.01 | 3.38 | 1.05 | |
| 1.01 | 0.97 | 0.84 | 1 | 0.88 | 1.01 | 0.89 | 0.9 | ||
| 0.951 | 0.781 | 0.049 | 0.995 | 0.228 | 0.941 | 0.066 | 0.306 | ||
Notes:
p < 0.07.
p < 0.05.
p < 0.01.
p < 0.001.
Detailed results of the multivariate regression analyses.
| Study 1 | Study 2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| STAI-T | HADS-D | BFI-N | PSS | F–D | STAI-T | BDI-13 | BFI-N | PSS | F–D | ||
| Latent Factor 1 (LF1) | 1.17 | 0.22 | 0.72 | 0.73 | −0.09 | 0.67 | 0.23 | 0.42 | 0.45 | −0.10 | |
| t | 8.13 | 4.74 | 6.40 | 6.17 | −3.36 | 7.04 | 4.88 | 5.87 | 5.81 | −6.00 | |
| <0.001 | <0.001 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
| Latent Factor 2 (LF2) | 0.32 | 0.21 | 0.07 | 0.19 | −0.23 | −0.14 | −0.06 | −0.04 | −0.03 | −0.06 | |
| t | 1.56 | 3.23 | 0.46 | 1.13 | −5.71 | −0.79 | −0.64 | −0.32 | −0.21 | −1.95 | |
| 0.120 | 0.001 | 0.646 | 0.261 | <0.001 | 0.433 | 0.523 | 0.750 | 0.833 | 0.053 | ||
| Latent Factor 3 (LF3) | 0.67 | 0.31 | 0.56 | 0.65 | −0.15 | 0.98 | 0.40 | 0.67 | 0.57 | −0.10 | |
| t | 1.72 | 2.53 | 1.83 | 2.02 | −1.93 | 3.96 | 3.21 | 3.66 | 2.84 | −2.42 | |
| 0.088 | 0.012 | 0.068 | 0.045 | 0.054 | <0.001 | 0.001 | <0.001 | 0.005 | 0.016 | ||
| Latent Factor 4 (LF4) | −0.20 | 0.03 | −0.36 | −0.03 | 0.01 | −0.16 | 0.06 | −0.26 | 0.02 | 0.03 | |
| t | −0.94 | 0.50 | −2.15 | −0.20 | 0.17 | −1.06 | 0.75 | −2.34 | 0.19 | 1.30 | |
| 0.346 | 0.618 | 0.033 | 0.844 | 0.868 | 0.290 | 0.451 | 0.020 | 0.846 | 0.195 | ||
Notes:
p < 0.07.
p < 0.05.
p < 0.01.
p < 0.001.
STAI-T, State-Trait Anxiety Inventory; HADS-D, Depression subscale of the Hospital Anxiety and Depression Scale; BDI-13, Beck Depression Inventory-13; BFI-N, Neuroticism dimension of the Big Five Inventory; PSS, Perceived Stress Scale; F–D, Difference score between functional and dysfunctional coping from Brief Cope.
Figure 1Associations between the latent factors and psychological and physical health measures.
Notes. p < 0.07, *p < 0.05, **p < 0.01, ***p < 0.001. B1 are the results of the analyses of Study 1 and B2 are the results of the analyses of Study 2.